

Appendix A. Model assumptions

Table A1. Age distribution of reported cases of COVID-19 in NSW, 29/6/2021 to 13/8/2021.

Age group	Cases
0-9*	734
10-19*	1100
20-29	1399
30-39	1064
40-49	752
50-59	710
60-69	371
≥70	319
Total	6449

*NSW Health reported 1834 cases in the 0-19 age group. Numbers based on assumption that 40% cases in the 0-19 age group were aged 0-9, and 60% were aged 10-19 age.

Sources:

NSW Government *NSW COVID-19 cases data*. 2021. <https://data.nsw.gov.au/nsw-covid-19-data/cases>. (31)

Australian Government Department of Health *Cases and deaths by age and sex*. Coronavirus (COVID-19) case numbers and statistics, 2021. <https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#cases-and-deaths-by-age-and-sex>. (32)

Table A2. Age distribution of reported cases of COVID-19 in Australia, January to December 2020.

Age group	Cases
0-9	1480
10-19	2416
20-29	6419
30-39	5072
40-49	3687
50-59	3417
60-69	2445
≥70	3713
Total	28649

Sources:

Australian Government Department of Health *COVID-19 summary statistics*. Coronavirus (COVID-19) case numbers and statistics, 2021. <https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics>. (14)

Australian Government Department of Health *National Notifiable Diseases Surveillance System public datasets*. 2021. <https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-pub-datasets.htm>. (33)

Table A3. Cases, deaths, and case fatality rate of COVID-19 in Australia by age and gender, January 2020 to 31/8/2021.

Age group	Male			Female		
	Cases	Deaths	Case fatality	Cases	Deaths	Case fatality
0-9	2848	0	0%	2317	0	0%
10-19	3298	1	0.03%	3196	0	0%
20-29	6162	2	0.03%	5859	0	0%
30-39	4975	4	0.08%	4511	2	0.04%
40-49	3468	3	0.09%	3178	2	0.06%
50-59	2935	11	0.37%	2798	8	0.29%
60-69	1862	35	1.88%	1735	14	0.81%
≥70	2042	444	21.74%	2512	480	19.11%
Total	27,226	500	1.84%	26,106	506	1.94%

Sources:

Australian Government Department of Health *COVID-19 summary statistics*. Coronavirus (COVID-19) case numbers and statistics, 2021. <https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics>. (14)

Australian Government Department of Health *National Notifiable Diseases Surveillance System public datasets*. 2021. <https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-pub-datasets.htm>. (33)

Table A4. Probability of infection (over 6 months) based on different intensities of community transmission.

Intensity of community transmission	Cases per 100,000 over 16 weeks*	Cases per million over 6 months	Estimated % of population infected over 6 months
Zero	0	0	0%
Low*	29	471	0.047%
Medium*	275	4,469	0.447%
High*	3,544	57,590	5.759%
1% over 6 months		10,000	1.0%
2% over 6 months		20,000	2.0%
200 cases/day in NSW ^a		4,455	0.446%
1000 cases/day in NSW ^a		22,276	2.228%
1000 cases/day in VIC ^b		27,289	2.729%
1000 cases/day in QLD ^c		35,067	3.507%

* Definitions of low, medium, and high transmission (cases per 100,000 over 16 weeks) as defined by ATAGI document ‘Weighing up the potential benefits and risk of harm from COVID-19 Vaccine AstraZeneca’. Low – similar to first wave in Australia. Medium – similar to second wave in VIC. High – similar to Europe in January 2021.

^aBased on NSW population of 8.17 million. ^bBased on VIC population of 6.67 million. ^cBased on QLD population of 5.19 million.

Source:

Australian Government Department of Health *COVID-19 vaccination – Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZenec*. 2021. <https://www.health.gov.au/resources/publications/covid-19-vaccination-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca>. (15)

Table A5. Relative risk of infection by age group and variant (chance of infection if overall probability of infection of 1% in all ages).

Age group	Alpha/wild	Delta
0-9	0.42%	0.92%
10-19	0.70%	1.42%
20-29	1.59%	1.54%
30-39	1.21%	1.13%
40-49	1.01%	0.91%
50-59	0.98%	0.90%
60-69	0.81%	0.55%
≥70	1.13%	0.43%
Overall	1.00%	1.00%

Table A6. Age distribution of Australian population, December 2020.

Age group	Population	% of total population
0-9	3,189,750	12.4%
10-19	3,086,855	12.0%
20-29	3,627,055	14.1%
30-39	3,755,673	14.6%
40-49	3,292,645	12.8%
50-59	3,138,303	12.2%
60-69	2,700,998	10.5%
≥70	2,958,236	11.5%
Total	25,749,515	100%

Source:

Australian Bureau of Statistics *Data downloads - time series spreadsheets*. National, state and territory population, 2021.

<https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/dec-2020#data-download>. (40)

Table A7. Estimated background incidence and fatality of atypical blood clots (CVST and PVT combined) over 6 weeks (in populations who have not received AZ vaccine and not diagnosed with COVID-19).

Age group	Incidence of atypical blood clots (CVST and PVT) over 6 weeks (per million)	Fatality rates from atypical blood clots (CVST and PVT) over 6 weeks (per million)	Overall case fatality rate from atypical blood clots (CVST and PVT)
0-9	0.38	0.03	7.0%
10-19	0.38	0.03	7.0%
20-29	0.84	0.10	11.8%
30-39	0.90	0.12	12.8%
40-49	1.20	0.20	16.3%
50-59	1.66	0.30	18.0%
60-69	2.51	0.53	21.0%
≥70	2.69	0.58	21.6%

Appendix B.

Examples of scenarios used for manual model validation.

Assume transmission of delta variant only for all scenarios.

1. For a 30-39 year-old male, what is the chance of symptomatic infection under high transmission if: a) Not vaccinated, b) had one dose of AZ vaccine, c) had two doses of AZ vaccine.
2. or a 30-39 year-old male, what is the overall chance of dying under high transmission if: a) Not vaccinated, b) had one dose of AZ vaccine, c) had two doses of AZ vaccine.
3. For a million 50-59 year-old females, if 70% had first dose, and 35% had two doses: a) How many cases of vaccine induced TTS would we expect? b) How many TTS related deaths would we expect?
4. For a million 70+ year-old males, if 70% had first does, and 35% had two doses: a) How many symptomatic cases would we expect over 6 months if there was ATAGI medium transmission during this time? B) How many deaths would we expect over 6 months if there was ATAGI medium transmission during this time?
5. If a 60-69 year-old female was diagnosed with COVID-19: a) what are her chances of developing atypical blood clots (CVST and PVT)? b) what are her chances of dying from atypical blood clots (CVST and PVT)?

Appendix C.

Table C1. Comparison of deaths prevented by AstraZeneca COVID-19 vaccine vs deaths from vaccine-associated Thrombosis with Thrombocytopenia Syndrome (TTS) under different intensities of community transmission. Assuming transmission of delta variant; 30% of unvaccinated, 70% received first dose, 35% received two doses; vaccine effectiveness against death of 69% after 1st dose, 90% after 2nd dose; age-specific TTS incidence and case-fatality rate (5%) reported by ATAGI on 25th August 2021.

Age group (years)	Community transmission intensity ^a (probability of infection over 6 months)	Estimated COVID-19 deaths over 6 months (per million ^b)		Estimated COVID-19 deaths prevented over 6 months if 70% had 1st dose, 35% had 2 doses (per million ^b)	Estimated cases of vaccine-associated TTS if 70% had 1st dose, 35% had 2 doses (per million ^b)	Estimated deaths from vaccine-associated TTS if 70% had 1st dose, 35% had 2 doses (per million ^b)	Estimated deaths prevented per vaccine-associated death from TTS
		0% vaccinated	70% had 1st dose, 35% had 2 doses				
All ages ≥10 ^c	Low (0.047%)	5.2	2.0	3.2	17.2	0.9	3.7
	Medium (0.447%)	49.2	19.0	30.2			35.1
	High (5.76%)	634.3	245.1	389.3			452.6
10-19	Low (0.047%)	<0.1	<0.1	<0.1	18.1	0.9	0.1
	Medium (0.447%)	1.0	0.4	0.6			0.7
	High (5.76%)	12.4	4.8	7.6			8.4
20-29	Low (0.047%)	0.1	<0.1	<0.1	18.1	0.9	0.1
	Medium (0.447%)	1.1	0.4	0.7			0.8
	High (5.76%)	14.4	5.6	8.8			9.7
30-39	Low (0.047%)	0.3	0.1	0.2	18.1	0.9	0.2
	Medium (0.447%)	3.2	1.2	1.9			2.1
	High (5.76%)	40.6	15.7	24.9			27.4
40-49	Low (0.047%)	0.3	0.1	0.2	18.1	0.9	0.2
	Medium (0.447%)	3.1	1.2	1.9			2.1
	High (5.76%)	39.2	15.2	24.1			26.5
50-59	Low (0.047%)	1.4	0.5	0.9	19.5	1.0	0.9
	Medium (0.447%)	13.3	5.2	8.2			8.4
	High (5.76%)	171.9	66.4	105.5			107.6
60-69	Low (0.047%)	3.5	1.3	2.1	11.8	0.6	3.6
	Medium (0.447%)	32.9	12.7	20.2			34.2
	High (5.76%)	424.3	163.9	260.4			441.3
≥70	Low (0.047%)	41.4	16.0	25.4	13.6	0.7	37.4
	Medium (0.447%)	393.0	151.8	241.2			354.7
	High (5.76%)	5064.8	1956.8	3108.0			4570.6

^a Definitions of community transmission intensity based on ATAGI document 'Weighing up the potential benefits and risk of harm from AstraZeneca COVID-19 vaccine. Low transmission: similar to first wave in Australia in 2020 (equivalent to 0.05% of population infected over 6 months). Medium transmission: similar to second wave in Victoria, Australia in 2020 (equivalent to 0.45% of population infected over 6 months). High transmission: similar to Europe in January 2021 (equivalent to 5.76% of population infected over 6 months).

^b Per million population of each age group, or per million of all ages based on population distribution of Australia

^c Calculations for all ages based on population distribution of Australia